First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75 ...

doi:10.1002/ski2.120 Bursal Duramaz B, Yozgat CY, Yozgat Y, Turel O. Appearance of skin rash in pediatric patients with COVID-19: three case presentations. Dermatol Ther. 2020;33(4):e13594.

Channel 4's online TV service - now renamed Channel 4 Streaming but it's shortened to C4 – allows you to catch-up on programmes, stream live channels and dip into the archives to watch older shows, ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients ... and laboratory abnormalities,” he added. Grade 3 or greater treatment-related AEs (TRAEs ...

Upon improvement to Grade 1 or less ... mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

and rash. No Grade 4 or 5 adverse events were observed. The safety profile of the rezatapopt and pembrolizumab combination has been consistent with each agent as monotherapy with no new safety signals ...

The regimen was associated with reversible grade 3 or 4 transaminase elevations in 10%, and 20% of patients missed one or more doses of pembrolizumab due to adverse ... (9%), pneumonitis (5%) and rash ...

You may also hear people calling roseola sixth disease. The simple explanation for that is that roseola was the sixth childhood rash (like measles) that scientists named. Most of the time ...

Muscle weakness and a skin rash are the main symptoms. Dermatomyositis isn't a common condition. Fewer than 5,000 people in the United States have it. It’s most common in two age groups ...

Only 10 % of patients with stage 4 bladder ... (≥3 %) Grade 3 or higher adverse events related to treatment with enfortumab vedotin and pembrolizumab were maculo-papular rash, hyperglycemia ...